IS1553B - Lyfjaform með langvarandi verkun - Google Patents

Lyfjaform með langvarandi verkun

Info

Publication number
IS1553B
IS1553B IS3214A IS3214A IS1553B IS 1553 B IS1553 B IS 1553B IS 3214 A IS3214 A IS 3214A IS 3214 A IS3214 A IS 3214A IS 1553 B IS1553 B IS 1553B
Authority
IS
Iceland
Prior art keywords
long
pharmaceutical form
active compound
acting pharmaceutical
weight
Prior art date
Application number
IS3214A
Other languages
English (en)
Icelandic (is)
Other versions
IS3214A7 (is
Inventor
Falk
Hugosson
Rosinski
SJöGREN
Original Assignee
Aktiebolaget Hässle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20364135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1553(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktiebolaget Hässle filed Critical Aktiebolaget Hässle
Publication of IS3214A7 publication Critical patent/IS3214A7/is
Publication of IS1553B publication Critical patent/IS1553B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS3214A 1986-04-11 1987-04-10 Lyfjaform með langvarandi verkun IS1553B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8601624A SE8601624D0 (sv) 1986-04-11 1986-04-11 New pharmaceutical preparations

Publications (2)

Publication Number Publication Date
IS3214A7 IS3214A7 (is) 1987-10-12
IS1553B true IS1553B (is) 1994-08-10

Family

ID=20364135

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3214A IS1553B (is) 1986-04-11 1987-04-10 Lyfjaform með langvarandi verkun

Country Status (34)

Country Link
US (1) US4803081A (enExample)
EP (1) EP0249587B1 (enExample)
JP (1) JPH0778016B2 (enExample)
KR (2) KR870009720A (enExample)
CN (1) CN1025150C (enExample)
AT (1) ATE76288T1 (enExample)
AU (1) AU602677B2 (enExample)
CA (1) CA1304294C (enExample)
CS (1) CS270560B2 (enExample)
CY (1) CY1826A (enExample)
DD (1) DD263231A5 (enExample)
DE (1) DE3779183D1 (enExample)
DK (1) DK173033B1 (enExample)
DZ (1) DZ1067A1 (enExample)
EG (1) EG18265A (enExample)
ES (1) ES2031929T3 (enExample)
FI (1) FI91826C (enExample)
GR (1) GR3005286T3 (enExample)
HK (1) HK26795A (enExample)
HU (1) HU204699B (enExample)
IE (1) IE59419B1 (enExample)
IS (1) IS1553B (enExample)
MY (1) MY101553A (enExample)
NO (1) NO174795B (enExample)
NZ (1) NZ219633A (enExample)
PH (1) PH22494A (enExample)
PL (1) PL265078A1 (enExample)
PT (1) PT84663B (enExample)
SE (1) SE8601624D0 (enExample)
SG (1) SG4295G (enExample)
SU (1) SU1743332A3 (enExample)
UA (1) UA12336A (enExample)
YU (1) YU47258B (enExample)
ZA (1) ZA871911B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
WO1993011668A1 (en) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
RU2121830C1 (ru) * 1992-09-18 1998-11-20 Яманоути Фармасьютикал Ко., ЛТД Гидрогелевый препарат с длительным высвобождением лекарства
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
CA2231195C (en) * 1996-07-08 2003-01-21 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19882037T1 (de) 1997-01-30 1999-12-16 Novartis Ag Hartgelatinekapsel, die im wesentlichen ölfreie pharmazeutische Zusammensetzungen enthält
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
EP1135106B1 (en) * 1999-09-30 2008-04-09 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
CA2405046C (en) * 2000-04-11 2009-06-23 Sankyo Company, Limited Stabilized pharmaceutical compositions comprising a calcium blocker and an alkaline material
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
WO2002056883A1 (en) * 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
WO2003004032A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
JP2005509604A (ja) * 2001-09-28 2005-04-14 マクニール−ピーピーシー・インコーポレイテッド 菓子組成物を含む剤形
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
WO2003084517A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
AU2003290060A1 (en) * 2002-12-17 2004-07-09 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
PL1915137T3 (pl) * 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US9419566B2 (en) 2011-04-20 2016-08-16 Freescale Semiconductor, Inc. Amplifiers and related integrated circuits
CN104997750B (zh) * 2015-07-30 2018-03-20 杭州康恩贝制药有限公司 一种非洛地平缓释片及其制备方法
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
CN109200026B (zh) * 2017-07-03 2021-01-05 北京四环科宝制药有限公司 一种非洛地平缓释片及其制备方法
CA3103616A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
JPS5495721A (en) * 1978-01-11 1979-07-28 Nippon Kayaku Co Ltd Nifedipine preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
JPS618A (ja) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk ニフエジピン含有製剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Also Published As

Publication number Publication date
DD263231A5 (de) 1988-12-28
YU40787A (sh) 1992-09-07
SU1743332A3 (ru) 1992-06-23
CA1304294C (en) 1992-06-30
NO871199D0 (no) 1987-03-23
PH22494A (en) 1988-09-12
CN1025150C (zh) 1994-06-29
CN87102758A (zh) 1987-10-21
IE870925L (en) 1987-10-11
FI91826B (fi) 1994-05-13
ATE76288T1 (de) 1992-06-15
SE8601624D0 (sv) 1986-04-11
NO871199L (no) 1987-10-12
HUT43786A (en) 1987-12-28
HK26795A (en) 1995-03-10
FI871585L (fi) 1987-10-12
PT84663B (pt) 1989-11-30
GR3005286T3 (enExample) 1993-05-24
AU7004387A (en) 1987-10-15
JPH0778016B2 (ja) 1995-08-23
DZ1067A1 (fr) 2004-09-13
EP0249587A1 (en) 1987-12-16
HU204699B (en) 1992-02-28
DE3779183D1 (de) 1992-06-25
DK154987D0 (da) 1987-03-26
MY101553A (en) 1991-12-17
FI91826C (fi) 1994-08-25
IS3214A7 (is) 1987-10-12
EG18265A (en) 1992-12-30
PL265078A1 (en) 1988-07-21
KR870009720A (ko) 1987-11-30
AU602677B2 (en) 1990-10-25
PT84663A (en) 1987-05-01
FI871585A0 (fi) 1987-04-10
DK154987A (da) 1987-10-12
UA12336A (uk) 1996-12-25
IE59419B1 (en) 1994-02-23
JPS62242613A (ja) 1987-10-23
NO174795B (no) 1994-04-05
NZ219633A (en) 1989-11-28
ES2031929T3 (es) 1993-01-01
DK173033B1 (da) 1999-11-29
CS270560B2 (en) 1990-07-12
NO174795C (enExample) 1994-07-13
CY1826A (en) 1995-12-01
YU47258B (sh) 1995-01-31
US4803081A (en) 1989-02-07
ZA871911B (en) 1987-12-30
SG4295G (en) 1995-06-16
CS258787A2 (en) 1989-11-14
KR890001521A (ko) 1989-03-27
EP0249587B1 (en) 1992-05-20
KR950002147B1 (ko) 1995-03-14

Similar Documents

Publication Publication Date Title
IS1553B (is) Lyfjaform með langvarandi verkun
KR900007837A (ko) 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법
ES2130111T3 (es) Derivados de ciclohexano, preparaciones que los contienen y su utilizacion.
DE3382637D1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
ATE16191T1 (de) Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten.
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
PT93991A (pt) Processo para a preparacao de solucoes estaveis de analogos de rebecamicina
NO843296L (no) Fremgangsmaate for fremstilling av benzosyrederivater med antimikrobiell aktivitet
FR2397191A1 (fr) Preparation stable de chloramphenicol pour injections
FR2446831A1 (fr) Derive oxyimino-e-homo-eburnane, procede pour le preparer et son utilisation dans une composition pharmaceutique pour la preparation de derives ester de l'acide apovincaminique
ES517779A0 (es) Procedimiento de preparacion de nuevos derivados de 2-fenilmorfolina.
BE877050A (fr) Utilisation d'esters d'acides hydroxycarboxyliques aliphatiques en tant que desodorisants
EP0023355A3 (en) Medicinal solutions and process for their preparation
ATE71529T1 (de) Pharmazeutische praeparate zur transdermalen applikation von heparin.
DE68905796D1 (de) Chromoglycinsaeure-natriumsalz enthaltende aerosolzubereitungen.
BG45854A3 (en) Method for preparing of alkylammonium salts of derivatives of 4- hydroxycumarine
SE7902817L (sv) Substituerade /4h/ 1,3-bensodioxin-2-karboxylsyraderivat, framstellning och anvendning derav sasom lekemedel samt farmaceutiska kompositioner innehallande dessa
TH2909A (th) องค์ประกอบสำหรับสิ่งที่ใช้ภายในปากและวิธีทำให้สารออกฤทธิ์คงตัวอยู่ภายในองค์ประกอบสำหรับสิ่งที่ใช้ภายในปาก
IT7949944A0 (it) Derivati di dossorubicina dotati di attivita' antitumorale procedimento per la loro preparazione e composizioni che li contengono
TH3206A (th) สารแขวนลอยซูครัลเฟท